ADRB3 and cancer: Zhou et al. found that the loss of the β3 adrenergic receptor (ADRB3) gene affects the PMN of malignant tumor cells, while ADRB3-induced NETs can persist for an extended period and contribute to the generation of PMN, thereby protecting disseminated tumor cells (DTC) from rejection by cytotoxic T lymphocytes 97.